Fate Therapeutics, Inc. - FATE STOCK NEWS

Fate Therapeutics, Inc. (NASDAQ: FATE) reported business highlights and financial results for the second quarter ended June 30, 2023. The company has shown resilience in advancing its innovative programs while reducing expenses, ending 2Q23 with $385 million in cash, cash equivalents, and investments, supporting a runway into 2H25. It has commenced Phase 1 study start-up for FT522 ADR-armed, CD19-targeted CAR NK cell program for B-cell lymphoma and initiated GMP manufacturing of FT825/ONO-8250 under the solid tumor collaboration with ONO Pharmaceutical. The company's FT819 program is advancing in single-dose escalation cohorts for B-cell malignancies, and a 2H23 IND submission is planned for the HER2-targeted CAR T-cell program for solid tumors.

Fate Therapeutics, Inc. (FATE) to Report Q2 2023 Financial Results and Corporate Update

Fate Therapeutics reports business highlights and financial results for Q1 2023. The company is focusing on its CAR NK and CAR T-cell pipeline, with ongoing studies and clinical assessments. They have also completed corporate restructuring and have a strong cash position of $426 million.

Fate Therapeutics, a clinical-stage biopharmaceutical company, will host a conference call on May 3, 2023, at 5:00 PM ET to discuss its financial results for Q1 2023. The company is pioneering induced pluripotent stem cell (iPSC)-derived cellular immunotherapies aimed at treating cancer and autoimmune disorders. Participants can register for the call via a provided link and access the live webcast on the company’s website, under the 'Investors' section. An archived version of the webcast will be available shortly after the event. Fate Therapeutics specializes in multiplexed-engineered iPSC lines and aims to deliver innovative cell therapies that incorporate synthetic controls such as chimeric antigen receptors (CARs).

Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical firm, will present at two upcoming investor conferences. The events include the 43rd Annual TD Cowen Health Care Conference on March 8, 2023, in Boston and the Barclays Global Healthcare Conference on March 14, 2023, in Miami. Live webcasts of these presentations will be available on the company's website. Fate Therapeutics is focused on developing innovative induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to treat cancer and autoimmune diseases, leveraging its proprietary iPSC product platform.

Fate Therapeutics reported key business highlights and financial results for Q4 and FY 2022, ending with approximately $475 million in cash and cash equivalents. The company initiated multi-dose treatment cohorts in the FT576 Phase 1 study for multiple myeloma, showing promising interim data with objective responses. Plans for 2023 include IND submissions for FT522 targeting B-cell lymphoma, FT819 for aggressive B-cell lymphoma, and FT825/ONO-8250 for solid tumors. The termination of the Janssen collaboration raises concerns, as does a planned workforce reduction, expected to incur $12-$16 million in costs. Total revenue for Q4 was $44.4 million, while R&D expenses were $87.2 million.

Fate Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: FATE), announced a conference call on February 28, 2023, at 5:00 PM ET to discuss its fourth quarter and full year 2022 financial results. The company is focused on developing first-in-class induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune disorders. Its pipeline includes off-the-shelf iPSC-derived natural killer (NK) cells and T-cell product candidates that aim to work alongside existing cancer treatments. Archived webcasts will be available post-event on the company's website.